Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134463 | 0.84 | ALDH1A1 (0.53) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11676672 | 0.83 | ALDH1A1 (0.49) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9373599 | 0.80 | TLR4 (0.40) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6225021 | 0.80 | MAPT (0.44) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30032752 | 0.78 | MAPT (0.40) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11836705 | 0.77 | TLR4 (0.70) | TLR4 | |
| SCHEMBL12606807 | 0.77 | TLR4 (0.52) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL321283 | 0.77 | TLR4 (0.52) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2470785 | 0.76 | TLR4 (0.51) | TLR4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL276016 | 0.76 | TLR4 (0.51) | TLR4ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435645-B2 | Organoleptic compounds | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435645-B2 | Organoleptic compounds | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3339278-B1 | NOVEL ORGANOLEPTIC COMPOUNDS | INT FLAVORS & FRAGRANCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3339278-B1 | NOVEL ORGANOLEPTIC COMPOUNDS | INT FLAVORS & FRAGRANCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3339278-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | International Flavors & Fragrances Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339278-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | International Flavors & Fragrances Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2018-06-21 | — | — | US | disclosed |
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1922171-A | Pyrimidine derivatives | ASKA PHARM CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2002028183-A1 | FUNGICIDES | SYNGENTA LIMITED (GB) | 2002-04-11 | — | — | WO | disclosed |
| EP-0138527-A2 | Herbicidal pyrazole derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-3948939-A | 9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids | STERLING DRUG INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | TLR4 1492/4885ALDH1A1 2838/4885MAPT 4663/4885 |
| US-20180171263-A1 | NOVEL ORGANOLEPTIC COMPOUNDS | TRPA1, TRPV1, TRPV5 | TLR4 3544/4885ALDH1A1 143/4885MAPT 2278/4885 |
| US-10435645-B2 | Organoleptic compounds | TRPA1, TRPV1, TRPV5 | TLR4 3508/4885ALDH1A1 141/4885MAPT 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.